Renal Cell Carcinoma (RCC)

Disclaimer: > [!WARNING] Medical Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. Medical guidelines and best practices change rapidly; users should verify information with current local protocols.

1. Overview

Renal Cell Carcinoma (RCC) is the most common malignant tumour of the kidney, accounting for approximately 85-90% of all renal malignancies. [1] It arises from the epithelial cells of the renal tubular system, predominantly the proximal convoluted tubule. RCC represents 2-3% of all adult malignancies and exhibits a male predominance (male-to-female ratio approximately 2:1). [2]

The incidence of RCC has increased substantially over recent decades, primarily due to the widespread use of cross-sectional imaging, with over 50% of cases now discovered incidentally as small renal masses on imaging performed for unrelated indications. [3] This "incidentaloma" phenomenon has shifted the epidemiology toward earlier-stage disease detection, though paradoxically, the mortality rate has not declined proportionately.

Key Clinical Features:

• Often asymptomatic and detected incidentally on imaging
• Classic triad (haematuria, flank pain, palpable mass) present in less than 10% and indicates advanced disease
• Notorious for paraneoplastic syndromes (polycythaemia, hypercalcaemia, Stauffer's syndrome)
• Highly vascular tumours due to VEGF overproduction
• Resistant to conventional chemotherapy and radiotherapy
• Treatment paradigm: surgery for localised disease, immunotherapy/targeted therapy for metastatic disease

---

2. Visual Summary Panel

Image Integration Plan

[!NOTE] Image Generation Status: Molecular pathway diagrams (VHL-HIF-VEGF axis) and surgical decision algorithms are queued for visual enhancement.

Histological Subtypes at a Glance

---

3. Epidemiology

Incidence and Demographics

RCC incidence has risen by approximately 2% annually over the past two decades, with current age-standardized rates of 10-15 per 100,000 in developed nations. [2,4] This increase is largely attributable to enhanced detection through widespread use of CT and ultrasound imaging.

Key Demographic Patterns:

• Age: Peak incidence at 60-70 years; rare before age 40 except in hereditary syndromes
• Sex: Male predominance (M:F ratio ~2:1) across all histological subtypes [1]
• Geography: Highest rates in North America, Europe, and Australia; lowest in Asia and Africa
• Trend: Shift toward smaller, organ-confined tumours at diagnosis (T1a disease now represents ~40% of new diagnoses) [3]

Risk Factors

Established Risk Factors:

1. Smoking [5]

   • Dose-dependent increase in risk (RR ~1.5-2.0 for current smokers)
   • Risk persists for 10-15 years after cessation
   • Accounts for approximately 20-30% of RCC cases in men

2. Obesity [5]

   • Each 5 kg/m² increase in BMI associated with ~24% increased risk in men, ~34% in women
   • Mechanism: altered adipokine secretion, insulin resistance, chronic inflammation

3. Hypertension [5]

   • Independent risk factor even after adjusting for BMI and antihypertensive medications
   • RR ~1.6 for hypertensive individuals
   • Unclear if hypertension per se or underlying vascular dysfunction is causal

4. Chronic Kidney Disease and Dialysis

   • End-stage renal disease patients have 3-6 fold increased RCC risk [6]
   • Acquired cystic kidney disease (develops in 40-90% of dialysis patients) predisposes to RCC
   • Screening recommendations vary; some advocate annual renal ultrasound in long-term dialysis patients

5. Hereditary Syndromes (5-8% of RCC cases) [7]

   • Von Hippel-Lindau (VHL) Disease: 25-45% lifetime RCC risk, typically bilateral and multifocal clear cell RCC
   • Hereditary Papillary RCC (HPRC): MET gene mutation, Type 1 papillary RCC
   • Birt-Hogg-Dubé (BHD) Syndrome: FLCN gene mutation, chromophobe and hybrid oncocytic tumours
   • Hereditary Leiomyomatosis RCC (HLRCC): FH gene mutation, aggressive Type 2 papillary RCC

6. Occupational Exposures

   • Trichloroethylene (degreasing agents)
   • Cadmium (battery manufacturing, welding)
   • Asbestos (weak association)

Protective Factors:

• Moderate alcohol consumption (weak inverse association, mechanism unclear)
• High fruit and vegetable intake (potential antioxidant effect)

---

4. Molecular Pathophysiology

The VHL-HIF-VEGF Axis (Clear Cell RCC)

The molecular pathogenesis of clear cell RCC is intimately linked to dysregulation of the von Hippel-Lindau (VHL) tumour suppressor gene, located on chromosome 3p25. [8] Understanding this pathway is fundamental to both disease biology and targeted therapy.

Normal VHL Function:

1. Under normoxic conditions, VHL protein forms part of an E3 ubiquitin ligase complex
2. This complex targets Hypoxia-Inducible Factors (HIF-1α and HIF-2α) for proteasomal degradation
3. HIFs are transcription factors that drive adaptive responses to hypoxia

Pathological VHL Loss:

1. Bi-allelic VHL inactivation (deletion, mutation, or hypermethylation) occurs in ~90% of sporadic clear cell RCC [8]
2. Loss of functional VHL → HIF accumulation despite normal oxygen levels (constitutive "pseudohypoxia")
3. Accumulated HIF drives transcription of hypoxia-response genes:
   • VEGF (Vascular Endothelial Growth Factor): Angiogenesis → highly vascular tumours
   • PDGF (Platelet-Derived Growth Factor): Stromal proliferation
   • EPO (Erythropoietin): Red blood cell production → polycythaemia
   • GLUT1: Glucose uptake → glycogen accumulation → "clear cell" appearance
   • CAIX (Carbonic Anhydrase IX): pH regulation

Therapeutic Implications:

• VEGF pathway is the primary target for systemic therapy (TKIs: sunitinib, pazopanib; mAbs: bevacizumab)
• HIF-2α inhibitors (belzutifan) represent novel agents directly targeting the dysregulated transcription factor [9]

Other Molecular Subtypes

Papillary RCC:

• Type 1: MET gene mutations/amplifications, trisomy 7 and 17
• Type 2: Fumarate hydratase (FH) mutations (HLRCC syndrome), more aggressive biology

Chromophobe RCC:

• Multiple chromosome losses (1, 2, 6, 10, 13, 17, 21)
• Derived from intercalated cells of collecting duct
• Generally indolent behaviour

Collecting Duct/Medullary RCC:

• Loss of SMARCB1/INI1 (medullary subtype)
• Aggressive phenotype, poor response to systemic therapy

---

5. Clinical Presentation

The Changing Clinical Landscape

The clinical presentation of RCC has transformed dramatically over the past 30 years. Historically, the "classic triad" of haematuria, flank pain, and palpable abdominal mass was a hallmark teaching point. Today, this triad is present in fewer than 10% of cases and signifies advanced, often metastatic disease. [3,10]

Contemporary Presentation Patterns:

• Incidental Detection (50-60%): Small renal mass identified on imaging for unrelated indications (e.g., trauma, abdominal pain, other malignancy staging) [3]
• Local Symptoms (20-30%): Haematuria (microscopic or gross), flank pain, palpable mass
• Systemic Symptoms (10-20%): Weight loss, fever, night sweats, fatigue (constitutional "B" symptoms)
• Paraneoplastic Syndromes (10-40%): See dedicated section below
• Metastatic Presentation (20-30%): Symptoms from distant sites (bone pain, dyspnoea, neurological deficit)

Classic Triad (The "Too Late Triad")

When all three components are present, they typically indicate advanced disease (T3/T4 or metastatic):

1. Haematuria (40-60% of symptomatic cases)

   • Usually painless and intermittent
   • May be microscopic or frank (visible)
   • Mechanism: Tumour erosion into collecting system

2. Flank Pain (40-50% of symptomatic cases)

   • Dull, constant ache in costovertebral angle
   • May indicate capsular distension or retroperitoneal extension
   • Acute severe pain suggests haemorrhage or obstruction

3. Palpable Abdominal Mass (25-45% of symptomatic cases)

   • Ballotable mass in flank (bimanual palpation)
   • Moves with respiration
   • Suggests large (≥10cm) or anteriorly located tumour

Varicocele: A Subtle but Important Sign

Left-sided varicocele deserves special attention as a red flag sign in RCC.

Anatomical Basis:

• The left testicular vein drains into the left renal vein (at 90° angle)
• The right testicular vein drains directly into the IVC
• RCC tumour thrombus extending into the left renal vein → venous outflow obstruction → varicocele

Clinical Features of Pathological Varicocele:

• Sudden onset in middle-aged/elderly man (versus idiopathic varicocele in adolescence)
• Does NOT decompress when supine (non-reducible)
• Left-sided (anatomy-dependent; right-sided varicocele is very rare and should prompt IVC investigation)
• Associated with renal mass or haematuria

Diagnostic Approach: Any new-onset varicocele in a patient > 40 years warrants renal imaging to exclude RCC. [11]

Paraneoplastic Syndromes

RCC is notorious for paraneoplastic phenomena, occurring in 10-40% of cases. [12] These syndromes may predate tumour detection and can serve as diagnostic clues or markers of disease recurrence.

Major Paraneoplastic Syndromes:

1. Polycythaemia (1-5% of cases)

   • Mechanism: Ectopic EPO production by tumour cells (HIF-driven)
   • Elevated haematocrit (> 52% men, > 48% women) with normal oxygen saturation
   • Paradoxical: More common is anaemia of chronic disease (20-40% of cases)

2. Hypercalcaemia (10-20% of cases) [12]

   • Mechanism: PTHrP (parathyroid hormone-related peptide) secretion
   • Presents as fatigue, constipation, confusion ("stones, bones, groans, psychiatric overtones")
   • Poor prognostic indicator (associated with advanced disease)

3. Hypertension (20-40% of cases)

   • Mechanism: Renin secretion by tumour, arteriovenous shunting, or compression of renal artery
   • May persist or resolve after nephrectomy

4. Hepatic Dysfunction (Stauffer's Syndrome) (3-20% of cases) [13]

   • Non-metastatic hepatic dysfunction: elevated alkaline phosphatase, prolonged PT, hepatomegaly
   • May mimic liver metastases on imaging (hepatomegaly without focal lesions)
   • Hallmark: Resolves completely after nephrectomy
   • Mechanism: IL-6 and other cytokine release by tumour
   • Poor prognostic marker

5. Cachexia and Weight Loss

   • Cytokine-mediated (TNF-α, IL-6)
   • Present in 30% of advanced RCC

6. Amyloidosis (Rare)

   • AA amyloid deposition
   • Presents as nephrotic syndrome or hepatosplenomegaly

Clinical Pearl: Resolution of paraneoplastic syndrome after nephrectomy is a favourable sign; recurrence of syndrome may herald disease recurrence even before imaging detection.

---

6. Clinical Examination

A systematic examination should assess for local disease, metastatic spread, and paraneoplastic manifestations.

Abdominal Examination:

1. Inspection

   • Visible flank mass (very large tumours)
   • Surgical scars (prior renal surgery)
   • Dilated superficial veins (IVC obstruction)

2. Palpation

   • Bimanual ballottement: Place one hand in flank posteriorly, palpate anteriorly with other hand; renal masses are ballotable and move with respiration
   • Assess size, mobility, tenderness
   • Palpate liver edge (hepatomegaly in Stauffer's or metastatic disease)

3. Percussion

   • Shifting dullness (ascites in advanced disease)

4. Auscultation

   • Renal bruit (rare, suggests vascular involvement)

Scrotal Examination:

• Examine for varicocele (standing and supine positions)
• Non-reducible left varicocele is highly suggestive of renal vein involvement

General Examination:

1. Signs of Polycythaemia

   • Facial plethora, conjunctival injection
   • Splenomegaly (rare)

2. Signs of Anaemia

   • Pallor (more common than polycythaemia)

3. Cachexia/Wasting

   • Weight loss, temporal wasting, muscle loss

4. Hypercalcaemia

   • Confusion, lethargy (check mental status)

5. Metastatic Disease

   • Bone metastases: Focal bony tenderness (spine, ribs, pelvis)
   • Lung metastases: Respiratory distress, reduced air entry
   • Brain metastases: Focal neurological signs, papilloedema
   • Lymphadenopathy: Left supraclavicular node (Virchow's node)

Examination Findings Suggesting Advanced Disease:

• Palpable mass (usually > 10cm)
• Non-reducible varicocele
• Hepatomegaly (Stauffer's or metastatic)
• Lower limb oedema (IVC obstruction)
• Ascites

---

7. Investigations

Baseline Laboratory Studies

Urinalysis:

• Haematuria: Present in 40% of cases (microscopic or macroscopic)
• Dipstick + microscopy; exclude UTI as alternative cause

Full Blood Count (FBC):

• Anaemia (20-40%): Normocytic, normochromic (anaemia of chronic disease)
• Polycythaemia (1-5%): Elevated Hb/haematocrit from ectopic EPO

Renal Function:

• Urea and Creatinine: Baseline renal function (essential for surgical planning)
• eGFR: Assess for CKD; less than 45 mL/min increases perioperative risk and may preclude radical nephrectomy

Liver Function Tests (LFTs):

• Stauffer's Syndrome: Elevated ALP, GGT; prolonged PT; normal bilirubin
• Elevated LFTs may also indicate liver metastases (requires imaging correlation)

Serum Calcium:

• Hypercalcaemia (10-20%): Corrected calcium > 2.6 mmol/L
• Measure PTH to exclude primary hyperparathyroidism (PTH suppressed in malignancy)

Lactate Dehydrogenase (LDH):

• Prognostic biomarker in metastatic RCC (elevated LDH predicts poor outcome) [14]

Erythrocyte Sedimentation Rate (ESR):

• Non-specific inflammatory marker; elevated in ~50% (prognostic value in some studies)

Cross-Sectional Imaging

Triphasic CT Renal Protocol (Gold Standard) [15]

This is the definitive imaging modality for characterization and staging of renal masses.

Three Phases:

1. Unenhanced (Pre-Contrast) Phase

   • Establishes baseline attenuation
   • Differentiates calcification (high attenuation) from haemorrhage
   • Identifies fat within mass (e.g., angiomyolipoma: < -10 HU)

2. Corticomedullary (Arterial) Phase (25-30 seconds post-contrast)

   • Maximal tumour enhancement
   • RCC enhances avidly (typically > 15-20 HU increase from baseline) [15]
   • Assesses renal artery anatomy (surgical planning)
   • Detects tumour thrombus in renal vein

3. Nephrogenic (Excretory) Phase (90-180 seconds post-contrast)

   • Maximal renal parenchymal enhancement
   • Assesses collecting system (hydronephrosis, invasion)
   • Evaluates ureter and bladder

CT Findings Suggestive of RCC:

• Enhancement > 15 HU from baseline (key differentiator from benign cyst)
• Solid, heterogeneous mass (versus homogeneous simple cyst)
• Intralesional necrosis (irregular low-attenuation areas)
• Neovascularity (abnormal feeding vessels)

Staging Information from CT:

• T Stage: Size, renal vein/IVC thrombus, perirenal fat invasion, adrenal involvement
• N Stage: Retroperitoneal/hilar lymphadenopathy (nodes > 1cm suspicious)
• M Stage: Liver, adrenal, bone, peritoneal metastases

Renal Mass Biopsy: When Is It Indicated?

Percutaneous renal mass biopsy is NOT routinely performed if the patient is proceeding to surgical resection, as imaging characteristics are typically sufficient. [16]

Indications for Biopsy:

1. Active Surveillance for small renal mass: Confirm histology, grade (Fuhrman/ISUP)
2. Thermal Ablation planned: Histological confirmation required
3. Metastatic Disease: Tissue diagnosis to guide systemic therapy (histology, PD-L1 status)
4. Diagnostic Uncertainty: Lymphoma, abscess, atypical angiomyolipoma, metastasis to kidney
5. Solitary Kidney or bilateral masses: Confirm malignancy before irreversible treatment

Biopsy Performance:

• Diagnostic accuracy ~90-95% for malignancy [16]
• Histological subtype concordance ~90%
• Grade concordance ~70-80% (limited by tumour heterogeneity)
• Complications: Haematoma (5-10%), haematuria (5%), tumour seeding (less than 0.01%, extremely rare)

Contraindications:

• Coagulopathy (INR > 1.5, platelets less than 50,000)
• Uncontrolled hypertension
• Active UTI

Staging Investigations

CT Chest (Essential) [15]

• Detect pulmonary metastases (most common site, 50-60% of metastatic RCC)
• Classic "cannonball" metastases (well-circumscribed, multiple, variable sizes)
• Also detects mediastinal lymphadenopathy

Bone Scan or PET-CT (Selective):

• Indicated if:
  • Bone pain or elevated alkaline phosphatase
  • High-risk disease (T3/4, node-positive)
  • Preoperative staging for metastatic disease
• Bone metastases occur in 30-40% of metastatic RCC

MRI Brain (Selective):

• Indicated for:
  • Neurological symptoms
  • Metastatic disease elsewhere (brain metastases occur in 10% of metastatic RCC)
  • High-risk disease

MRI Abdomen (Alternative to CT):

• Preferred if:
  • Contrast allergy or renal impairment (gadolinium safer than iodinated contrast)
  • Superior assessment of IVC thrombus (multiplanar imaging, flow characteristics)
  • Young patients (avoid radiation)

TNM Staging (AJCC 8th Edition) [17]

T Stage (Primary Tumour):

• T1a: ≤4cm, limited to kidney
• T1b: > 4cm but ≤7cm, limited to kidney
• T2a: > 7cm but ≤10cm, limited to kidney
• T2b: > 10cm, limited to kidney
• T3a: Tumour extends into renal vein, perirenal fat, or sinus fat (not beyond Gerota's fascia)
• T3b: Tumour extends into IVC below diaphragm
• T3c: Tumour extends into IVC above diaphragm or invades IVC wall
• T4: Tumour invades beyond Gerota's fascia (including ipsilateral adrenal by direct extension)

N Stage (Regional Lymph Nodes):

• N0: No regional lymph node metastasis
• N1: Metastasis in regional lymph node(s)

M Stage (Distant Metastasis):

• M0: No distant metastasis
• M1: Distant metastasis

Stage Grouping:

• Stage I: T1, N0, M0
• Stage II: T2, N0, M0
• Stage III: T3, N0, M0 OR T1-3, N1, M0
• Stage IV: T4, any N, M0 OR any T, any N, M1

---

8. Management

The treatment of RCC has evolved significantly with advances in surgical technique (nephron-sparing approaches, minimally invasive surgery) and systemic therapy (immunotherapy, targeted agents). Management is primarily stage-dependent.

A. Localised Disease (Stage I-III)

Surgery remains the only curative modality for localised RCC. [18]

1. Partial Nephrectomy (Nephron-Sparing Surgery)

Indications (EAU/AUA Guidelines): [18,19]

• Standard of care for T1a tumours (less than 4cm)
• Preferred approach for T1b tumours (4-7cm) when technically feasible
• Imperative in patients with:
  • Solitary kidney
  • Bilateral RCC
  • Pre-existing CKD (eGFR less than 45 mL/min)
  • Hereditary RCC syndromes (VHL, BHD)

Rationale:

• Equivalent oncological outcomes to radical nephrectomy for T1 tumours (5-year CSS > 95%) [20]
• Superior renal functional preservation: Reduces risk of post-operative CKD by 20-30% compared to radical nephrectomy [20]
• Lower cardiovascular morbidity (CKD is independent CV risk factor)

Techniques:

• Open partial nephrectomy: Traditional gold standard, best for complex tumours
• Laparoscopic partial nephrectomy: Requires advanced laparoscopic skills
• Robotic-assisted partial nephrectomy: Increasingly preferred (shorter warm ischaemia time, lower complication rate vs laparoscopic) [21]

Key Surgical Principles:

• Negative margins (R0 resection): Margin width less than 1mm acceptable; wide margins not required [22]
• Minimise warm ischaemia time: Target less than 20-25 minutes (if clamping renal hilum)
• Trifecta outcomes: (1) Negative margins, (2) No complications, (3) Warm ischaemia less than 25 min

Complications:

• Haemorrhage (1-5%)
• Urine leak (1-10%, higher for centrally located tumours)
• Acute kidney injury (transient, usually resolves)
• Pseudoaneurysm (rare)

2. Radical Nephrectomy

Indications: [18]

• T2-T4 tumours (> 7cm or locally advanced)
• T1 tumours with unfavourable anatomy (hilar, endophytic, multiple)
• Intraoperative decision (unable to achieve negative margins with partial nephrectomy)

Standard Technique:

• En bloc resection of kidney, perirenal fat, Gerota's fascia, ipsilateral adrenal (if tumour in upper pole or imaging-suspicious adrenal)
• Lymphadenectomy: Not routinely indicated unless nodes clinically/radiologically enlarged (no survival benefit from routine template dissection) [18]

Approaches:

• Open (via flank or transperitoneal incision): For large/complex tumours, IVC thrombus
• Laparoscopic: Standard approach for T1-T2 disease
• Robotic-assisted: Emerging alternative to laparoscopic

IVC Tumour Thrombus (T3b/c):

• Present in 4-10% of RCC cases [23]
• Surgical approach depends on thrombus level:
  • "Infradiaphragmatic (T3b): Caval cross-clamping below and above thrombus"
  • "Supradiaphragmatic (T3c): Requires cardiopulmonary bypass, cardiothoracic surgery involvement"
• Complete thrombectomy + nephrectomy can achieve 40-60% 5-year survival in non-metastatic cases [23]

3. Active Surveillance (AS)

Concept: Small renal masses (SRMs, defined as less than 4cm) grow slowly (~0.3cm/year on average) and have low metastatic potential (1-2% over 5 years). [24] In elderly or comorbid patients, AS with serial imaging is a viable option.

Candidate Selection: [24]

• Tumour: Size less than 4cm (T1a), solid or complex cystic
• Patient: Elderly (> 75 years), significant comorbidities (ASA ≥3), limited life expectancy (less than 5-10 years)
• Patient preference: Informed decision after discussion of risks/benefits

Surveillance Protocol:

• Baseline CT/MRI
• Repeat imaging at 3-6 months, then every 6-12 months indefinitely
• Trigger for intervention: Growth rate > 0.5cm/year, symptoms, patient preference

Outcomes:

• ~50% of SRMs remain stable over 5 years [24]
• ~20-30% eventually undergo delayed intervention (growth, patient anxiety)
• Cancer-specific mortality less than 1% at 5 years

Patient Counselling: Active surveillance is not "watch and wait until too late." It is an active management strategy with planned serial imaging and low threshold for intervention if tumour behaviour changes.

4. Thermal Ablation

Modalities:

• Radiofrequency Ablation (RFA): Heat-based coagulative necrosis
• Cryoablation: Freeze-thaw cycles causing cellular ice crystal formation and apoptosis

Indications: [18]

• T1a tumours (less than 4cm), ideally less than 3cm
• Poor surgical candidates: Comorbidities precluding anaesthesia/surgery
• Solitary kidney or hereditary syndromes (may require multiple ablations over lifetime)

Technique:

• Image-guided (CT or ultrasound) percutaneous probe insertion
• General anaesthesia or conscious sedation

Outcomes:

• Oncological efficacy: Inferior to surgery (5-year local recurrence ~5-10% vs less than 5% for surgery) [25]
• Functional preservation: Excellent (minimal impact on eGFR)
• Morbidity: Lower than surgery (outpatient/short stay, faster recovery)

Ideal Tumour Characteristics for Ablation:

• Exophytic (> 50% extends beyond renal contour): Easier to target, less heat-sink effect
• Posterior location: Safer (away from bowel)
• Away from collecting system: Reduces urine leak risk

Complications:

• Haemorrhage (1-5%)
• Urine leak (rare with careful technique)
• Injury to adjacent organs (bowel, ureter, adrenal)

B. Metastatic Disease (Stage IV)

RCC is classically resistant to conventional chemotherapy and radiotherapy due to high expression of multi-drug resistance pumps (e.g., P-glycoprotein) and intrinsic radioresistance. The landscape of metastatic RCC (mRCC) management has been revolutionised by targeted therapy and immunotherapy. [26,27]

Risk Stratification: IMDC Criteria (International Metastatic RCC Database Consortium)

Prognostic risk stratification guides therapy selection. [14]

IMDC Risk Factors (1 point each):

1. Karnofsky Performance Status less than 80%
2. Time from diagnosis to systemic therapy less than 1 year
3. Haemoglobin < lower limit of normal
4. Calcium > upper limit of normal
5. Neutrophils > upper limit of normal
6. Platelets > upper limit of normal

Risk Groups:

• Favourable risk: 0 factors (median OS ~43 months)
• Intermediate risk: 1-2 factors (median OS ~23 months)
• Poor risk: ≥3 factors (median OS ~8 months)

First-Line Systemic Therapy (2024 Paradigm) [26,27,28]

Option 1: Combination Immunotherapy (Preferred for Most Patients)

Nivolumab + Ipilimumab [27]

• Mechanism: Dual checkpoint inhibition (PD-1 + CTLA-4)
• Dosing: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg IV every 3 weeks x 4 doses, then Nivolumab 3 mg/kg (or 480mg flat dose) every 2-4 weeks
• Efficacy (CheckMate 214 trial): 42% ORR, 12% CR rate, median OS 47 months (vs 26 months for sunitinib) in intermediate/poor risk [27]
• Toxicity: Immune-related adverse events (irAEs): colitis, hepatitis, endocrinopathies (thyroid, hypophysitis), pneumonitis (~40% grade 3-4)
• Patient Selection: Intermediate/poor risk; clear cell histology

Option 2: Immunotherapy + TKI Combination

Pembrolizumab + Axitinib [28]

• Mechanism: PD-1 inhibitor + VEGFR TKI
• Efficacy: 59% ORR, median PFS 15.1 months, median OS 45.7 months
• Toxicity: Diarrhoea, hypertension, fatigue (TKI-related); irAEs (pembrolizumab)

Cabozantinib + Nivolumab [29]

• Efficacy: 55% ORR, median PFS 16.6 months
• Toxicity: Palmar-plantar erythrodysesthesia, diarrhoea, hypertension

Option 3: VEGFR TKI Monotherapy (Now Less Common First-Line)

Sunitinib (Historical Standard) [30]

• Mechanism: Multi-targeted TKI (VEGFR1/2/3, PDGFR, c-KIT)
• Dosing: 50mg PO daily x 4 weeks, then 2 weeks off (6-week cycle)
• Efficacy: 25-40% ORR, median PFS 11 months, median OS 26 months
• Toxicity: Fatigue, hand-foot syndrome, hypertension, diarrhoea, hypothyroidism, myelosuppression
• Patient Selection: Favourable-risk patients unwilling/unsuitable for immunotherapy

Pazopanib [31]

• Dosing: 800mg PO daily (continuous)
• Efficacy: Non-inferior to sunitinib
• Toxicity: Hepatotoxicity (requires LFT monitoring), hypertension, diarrhoea

Second-Line and Subsequent Therapy [26]

Post-Immunotherapy Progression:

• Cabozantinib (VEGFR/MET/AXL TKI): 21% ORR, median PFS 7.4 months [32]
• Lenvatinib + Everolimus: 43% ORR (highest second-line ORR) [33]

Post-TKI Progression:

• Nivolumab: 25% ORR, median OS 25 months (vs 19 months for everolimus) [34]
• Cabozantinib: PFS benefit vs everolimus

HIF-2α Inhibitor:

• Belzutifan [9]: FDA-approved for VHL-associated RCC; targets HIF-2α directly; 49% ORR in heavily pre-treated patients

Cytoreductive Nephrectomy (CN) in Metastatic Disease

Historical Practice: The SWOG 8949 trial (2001) demonstrated OS benefit of CN + interferon-α vs interferon alone (median OS 11.1 vs 8.1 months). [35]

Contemporary Controversy: Two recent trials (CARMENA, SURTIME) challenged routine CN in the immunotherapy era:

• CARMENA trial [36]: CN + sunitinib non-superior to sunitinib alone (median OS 13.9 vs 18.4 months)
• Interpretation: CN may harm intermediate/poor risk patients with high metastatic burden

Current Recommendations (EAU/NCCN): [18,26]

• CN considered in:
  • Favourable-risk patients with low metastatic burden
  • Symptomatic primary (pain, haematuria)
  • Good performance status (ECOG 0-1)
• CN NOT recommended in:
  • Poor-risk patients with high metastatic burden
  • Sarcomatoid histology
  • Brain/liver/bone metastases

Patient Selection Tools: Ongoing research (molecular biomarkers, imaging response to systemic therapy) aims to better identify CN candidates.

Metastasectomy (Surgical Resection of Metastases)

Concept: Complete surgical resection of all sites of metastatic disease in highly selected patients may prolong OS. [37]

Candidate Selection:

• Complete resection feasible (limited number and sites of metastases)
• Long disease-free interval (> 1-2 years from nephrectomy)
• Good performance status

Outcomes:

• 5-year OS post-metastasectomy: 35-50% (highly selected cohorts) [37]
• Favourable sites: Lung (best outcomes), soft tissue, solitary brain metastasis
• Unfavourable: Multiple organs, bone, liver

Role in Era of Effective Systemic Therapy: Metastasectomy remains viable for oligometastatic disease; systemic therapy often precedes or follows surgery.

---

9. Complications and Sequelae

A. Complications of the Disease

Metastatic Spread:

• Lung (50-60%): "Cannonball" metastases, dyspnoea, haemoptysis
• Bone (30-40%): Pathological fractures, spinal cord compression, hypercalcaemia
• Liver (20-40%): Hepatic dysfunction, portal hypertension (rare)
• Brain (10%): Seizures, focal neurological deficit, raised ICP
• Adrenal (5-10%): Often asymptomatic; rarely Addisonian crisis

Paraneoplastic Complications:

• Hyperviscosity syndrome (polycythaemia) → thromboembolism
• Hypercalcaemia → renal impairment, arrhythmia, coma
• Stauffer's syndrome → hepatic failure (rare)

Local Complications:

• IVC thrombus extension: Budd-Chiari syndrome, pulmonary embolism (if thrombus embolizes), right heart failure
• Renal vein thrombosis: Acute flank pain, haematuria, renal infarction
• Spontaneous tumour haemorrhage: Retroperitoneal haemorrhage (Wunderlich syndrome) → hypovolaemic shock

B. Complications of Treatment

Surgical Complications:

• Acute kidney injury: Especially post-radical nephrectomy in pre-existing CKD
• Chronic kidney disease: 20-40% develop eGFR less than 45 after radical nephrectomy [20]
• Haemorrhage: Intra-operative or delayed (pseudoaneurysm)
• Urine leak: 5-10% post-partial nephrectomy (usually self-limiting; stent if persistent)
• Injury to adjacent organs: Spleen, pancreas, liver, bowel (during adrenalectomy or extensive dissection)

Immunotherapy Complications (Immune-Related Adverse Events):

• Colitis: Diarrhoea, abdominal pain (treat with steroids; infliximab if steroid-refractory)
• Hepatitis: Transaminitis (may require permanent discontinuation)
• Endocrinopathies: Hypothyroidism (20-30%, often permanent; levothyroxine replacement), hypophysitis (adrenal insufficiency, hypogonadism), type 1 diabetes
• Pneumonitis: Dyspnoea, cough, infiltrates on imaging (high-dose steroids)
• Nephritis: AKI (immune-mediated tubulointerstitial nephritis)

Management Principle for irAEs:

• Grade 1-2: Continue therapy + symptomatic management ± low-dose steroids
• Grade 3-4: Hold immunotherapy + high-dose steroids (prednisone 1-2 mg/kg/day) ± additional immunosuppression (infliximab, mycophenolate)
• Resume therapy only after resolution to ≤grade 1

TKI Complications:

• Hypertension (20-40%): Often requires antihypertensive (ACE inhibitor preferred)
• Hand-Foot Syndrome (palmar-plantar erythrodysesthesia): Painful erythema, blistering (dose reduction, topical urea)
• Diarrhoea: Loperamide; dose reduction if persistent
• Hypothyroidism (20-30%): Monitor TSH; levothyroxine replacement
• Cardiac: LV dysfunction, QTc prolongation (rare but serious)
• Hepatotoxicity: Regular LFT monitoring (especially pazopanib)

---

10. Prognosis and Outcomes

Stage-Specific Survival

Prognosis is heavily stage-dependent at diagnosis.

5-Year Overall Survival by Stage (SEER Data): [38]

• Stage I (T1, N0, M0): 93%
• Stage II (T2, N0, M0): 85%
• Stage III (T3/N1, M0): 59%
• Stage IV (M1): 12% (pre-immunotherapy era; improving with modern therapy)

5-Year Cancer-Specific Survival by T Stage:

• T1a (less than 4cm): > 95%
• T1b (4-7cm): 88-92%
• T2 (7-10cm): 74-82%
• T3a (perirenal invasion, renal vein): 53-60%
• T3b/c (IVC thrombus): 40-50% (if node-negative, metastasis-free)
• T4 (beyond Gerota's): 20-30%

Prognostic Factors

Favourable Prognostic Factors:

• Small tumour size (T1)
• Organ-confined disease
• Clear cell histology (better response to VEGF-targeted therapy)
• Low Fuhrman/ISUP grade (1-2)
• Absence of sarcomatoid features
• No nodal involvement
• Incidental detection (vs symptomatic)

Unfavourable Prognostic Factors:

• Symptomatic presentation (classic triad)
• Sarcomatoid differentiation (dedifferentiated, aggressive phenotype)
• Nodal metastases (N1)
• Tumour necrosis (on histology)
• Microvascular invasion
• Collecting duct or medullary subtypes
• Elevated LDH, calcium, neutrophils, platelets (IMDC criteria)

Prognostic Models

Leibovich Score (Post-Nephrectomy Prognostic Score): [39] Predicts metastasis-free survival after surgery for localised RCC.

Variables (points assigned for adverse features):

• T stage (2-4 points)
• Node-positive (2 points)
• Tumour size (≥10 cm: 1 point)
• Nuclear grade (1-3 points)
• Tumour necrosis (1 point)

Risk Groups:

• Low (0-2 points): 97% metastasis-free at 5 years
• Intermediate (3-5 points): 75%
• High (≥6 points): 31%

SSIGN Score (Stage, Size, Grade, Necrosis): [40] Alternative validated model incorporating similar variables.

Recurrence After Surgery

Recurrence Risk:

• Overall: 20-40% of patients develop recurrence after nephrectomy for localised disease
• Higher risk: T3-4, node-positive, grade 3-4, sarcomatoid features
• Median time to recurrence: 1-2 years (but can occur > 10 years later)

Surveillance After Curative-Intent Surgery (EAU Guidelines): [18]

Low Risk (T1a, Grade 1-2):

• Baseline CT chest/abdomen/pelvis at 6-12 months
• Annual imaging x 3 years, then discharge (or less frequent imaging)

Intermediate Risk (T1b-T2, Grade 3):

• CT chest/abdomen/pelvis every 6 months x 2 years, then annually to 5 years

High Risk (T3-4, N1, Grade 4, Sarcomatoid):

• CT chest/abdomen/pelvis every 3-6 months x 3 years, then annually to 10 years

Rationale for Prolonged Surveillance: Late recurrences (> 5 years) occur in 10-15% of patients; lifetime surveillance may be warranted for high-risk cases.

---

11. Hereditary RCC Syndromes

Approximately 5-8% of RCC cases are hereditary. Recognition of these syndromes is critical for patient management (earlier screening, bilateral surgery, family counselling). [7]

Von Hippel-Lindau (VHL) Disease

Genetics:

• Autosomal dominant, chromosome 3p25 (VHL gene)
• Penetrance ~90% by age 65

Clinical Features:

• RCC: 25-45% lifetime risk; bilateral, multifocal, clear cell; typically presents age 30-50 (vs 60-70 for sporadic)
• CNS hemangioblastomas: Cerebellum, brainstem, spinal cord (60-80%)
• Retinal angiomas (50-60%)
• Phaeochromocytomas (10-20%)
• Pancreatic neuroendocrine tumours, cysts (50-70%)
• Endolymphatic sac tumours (hearing loss)

Screening Recommendations:

• Annual renal imaging (MRI or CT) starting age 16
• Annual ophthalmologic exam
• Annual urine/plasma metanephrines (phaeochromocytoma screening)
• MRI brain/spine every 2 years

RCC Management in VHL:

• Nephron-sparing surgery is imperative (bilateral disease, repeated surgeries over lifetime)
• "3cm Rule": Intervene when largest tumour reaches 3cm (balances oncological control with renal preservation) [7]
• Belzutifan (HIF-2α inhibitor): Approved for VHL-associated RCC; can shrink tumours and delay need for surgery [9]

Hereditary Papillary RCC (HPRC)

Genetics:

• Autosomal dominant, MET proto-oncogene mutation (chromosome 7q31)

Features:

• Bilateral, multifocal Type 1 papillary RCC (indolent)
• Presents age 40-60

Management:

• Similar to VHL: nephron-sparing surgery, surveillance

Birt-Hogg-Dubé (BHD) Syndrome

Genetics:

• Autosomal dominant, FLCN gene (chromosome 17p11.2)

Features:

• RCC: 15-30% lifetime risk; chromophobe and hybrid oncocytic subtypes (not clear cell)
• Cutaneous fibrofolliculomas (face, neck): Pathognomonic
• Spontaneous pneumothorax (recurrent, due to pulmonary cysts)

Management:

• Annual renal imaging starting age 20
• CT chest for lung cysts
• Nephron-sparing surgery for RCC

Hereditary Leiomyomatosis and RCC (HLRCC)

Genetics:

• Autosomal dominant, fumarate hydratase (FH) gene mutation (chromosome 1q42-43)

Features:

• RCC: 10-20% lifetime risk; aggressive Type 2 papillary RCC
• Cutaneous leiomyomas (painful skin nodules)
• Uterine leiomyomas (fibroids, early onset)

Management:

• Annual renal MRI (more sensitive than CT for small lesions) starting age 8-10
• Early aggressive surgery (even for small tumours, due to aggressive biology)
• Consider prophylactic hysterectomy for symptomatic uterine fibroids

---

12. Emerging Therapies and Future Directions

Novel Systemic Agents

HIF-2α Inhibitors:

• Belzutifan (MK-6482): First-in-class oral HIF-2α inhibitor [9]
• FDA-approved for VHL-associated RCC, ccRCC in certain settings
• Targets the root molecular driver in VHL-mutated tumours
• Future: Potentially first-line therapy for ccRCC

Antibody-Drug Conjugates (ADCs):

• CAIX-targeted ADCs: Carbonic anhydrase IX (CAIX) is highly expressed in ccRCC
• Early clinical trials ongoing

Bispecific Antibodies:

• Engage T cells and tumour cells simultaneously
• Under investigation in RCC

Adjuvant and Neoadjuvant Therapy

Adjuvant Therapy (Post-Nephrectomy for High-Risk Disease):

Recent trials have demonstrated benefit of adjuvant therapy in high-risk localised RCC:

Pembrolizumab (KEYNOTE-564): [41]

• Population: High-risk RCC post-nephrectomy (T2 grade 4, T3-4, N+, M1 NED)
• Outcome: Improved disease-free survival (77.3% vs 68.1% at 24 months)
• FDA-approved 2021

Patient Counselling: Adjuvant pembrolizumab reduces recurrence risk but requires 1 year of treatment with irAE risk; shared decision-making essential.

Neoadjuvant Therapy (Pre-Operative Systemic Therapy):

• Rationale: Downstage tumour, enable nephron-sparing surgery, treat micrometastases early
• Early trials: Nivolumab, cabozantinib + nivolumab showing promise
• Status: Investigational; not standard practice

Personalised Medicine and Biomarkers

Current Limitations: No validated predictive biomarkers exist to guide first-line therapy choice (immunotherapy vs TKI vs combination).

Under Investigation:

• PD-L1 expression: Inconsistent predictive value in RCC (unlike lung cancer)
• Tumour mutational burden (TMB): Low in RCC; not useful
• Gene expression signatures: Angiogenesis, immune, stromal signatures (e.g., IMmotion150 trial) [42]
• Circulating tumour DNA (ctDNA): Early detection of recurrence, monitoring treatment response

Goal: Precision medicine approach to match patient to optimal therapy (immunotherapy responders vs TKI responders).

---

13. Special Populations

RCC in Young Patients (less than 40 Years)

• Represents ~5% of RCC cases
• Higher likelihood of hereditary syndrome (25-30% vs 3-5% in older patients) [7]
• Genetic counselling and germline testing recommended
• Generally better prognosis (stage-for-stage) than older patients

RCC in Chronic Kidney Disease and Dialysis Patients

• Acquired cystic kidney disease (ACKD): Develops in 40-90% of dialysis patients; RCC risk 3-6 fold higher [6]
• Screening: Controversial; some advocate annual ultrasound in long-term dialysis patients
• Management: Partial nephrectomy preferred (preserve residual function); radical nephrectomy if no residual function
• Transplant consideration: RCC history may affect transplant eligibility (usually require 2-year disease-free interval)

RCC in Pregnancy

• Extremely rare (less than 50 cases in literature)
• Management dilemma: Balance maternal oncological outcomes with fetal safety
• Case-by-case approach: Multidisciplinary team (urology, oncology, maternal-fetal medicine)
• Small, stable tumours → surveillance until delivery; large/symptomatic → surgery (preferably second trimester)

---

14. Patient and Layperson Explanation

What is Kidney Cancer?

Kidney cancer (renal cell carcinoma or RCC) is a type of cancer that starts in the kidney, specifically in the tiny tubes (tubules) that filter your blood to make urine. It's the most common type of kidney tumour in adults, accounting for about 85-90% of kidney cancers.

Why Did I Get It?

The exact cause isn't always clear, but several factors increase your risk:

• Smoking: The single biggest preventable risk factor—it doubles your risk
• Obesity: Being overweight increases risk, especially in women
• High blood pressure: Though it's unclear if it's the blood pressure itself or related factors
• Dialysis: Long-term dialysis patients have higher risk
• Family history: Some kidney cancers run in families (Von Hippel-Lindau disease, for example)

In many cases, kidney cancer develops by chance as we age, even without these risk factors.

Why Don't I Have Any Symptoms?

This is actually good news. Most kidney cancers today are found "by accident" when you have a CT scan or ultrasound for something completely unrelated (like gallstones, back pain, or a motor vehicle accident). Finding it early—before it causes symptoms—means it's usually smaller and easier to cure.

When kidney cancer does cause symptoms (usually only in advanced cases), they include:

• Blood in the urine (may be visible or microscopic)
• Flank pain (dull ache in the side, below the ribs)
• A lump you or your doctor can feel in your abdomen

If you have all three of these ("classic triad"), it often means the cancer has grown quite large. That's why finding it early, before symptoms, is ideal.

What Happens Next?

Step 1: Imaging (CT Scan) You'll have a special CT scan called a "triphasic renal CT" where you get contrast dye injected, and images are taken at different times. This shows whether the kidney mass is cancer (cancers "light up" with contrast) or a harmless cyst (cysts don't light up).

Step 2: Staging Your doctor will assess the cancer's stage (how big it is and whether it's spread):

• Stage I-II: Cancer confined to the kidney (best prognosis)
• Stage III: Cancer has grown into nearby tissues or lymph nodes
• Stage IV: Cancer has spread to distant organs (lungs, bones, liver, brain)

Step 3: Treatment Discussion Your treatment depends on the stage, your kidney function, and your overall health.

Treatment Options

For Early-Stage Cancer (Localised, Confined to Kidney):

1. Partial Nephrectomy (Kidney-Sparing Surgery) This is the gold standard for small kidney cancers (less than 4cm, sometimes up to 7cm). The surgeon removes just the tumour and a small rim of normal tissue, leaving the rest of your kidney intact. This:

• Cures the cancer (> 95% cure rate for small cancers)
• Preserves your kidney function (important for long-term health)
• Can be done through small incisions (laparoscopic or robotic surgery)

2. Radical Nephrectomy (Removal of Entire Kidney) For larger cancers or those in difficult locations, the whole kidney is removed. Don't worry—one kidney is enough. Your remaining kidney will compensate, and most people live normal lives with one kidney.

3. Active Surveillance ("Watchful Waiting") If you're elderly or have serious medical problems, and the cancer is small and slow-growing, your doctor may recommend regular imaging (every 6-12 months) instead of immediate surgery. Many small kidney cancers grow very slowly and may never cause problems.

4. Ablation (Burning or Freezing the Tumour) For small cancers in patients who can't have surgery, a radiologist can insert a needle into the tumour and destroy it with heat (radiofrequency ablation) or freezing (cryotherapy). It's less invasive than surgery but has a slightly higher risk of cancer coming back.

For Advanced Cancer (Metastatic, Spread Beyond Kidney):

Kidney cancer is resistant to traditional chemotherapy and radiotherapy. However, modern targeted drugs and immunotherapy have transformed outcomes.

1. Immunotherapy Drugs like nivolumab and ipilimumab teach your immune system to recognise and attack cancer cells. These drugs can shrink tumours and prolong life—some patients live for years with metastatic kidney cancer on these drugs.

Side effects: Immune system can attack normal organs (gut, liver, thyroid, lungs)—closely monitored and treated with steroids if needed.

2. Targeted Therapy Drugs like sunitinib, pazopanib, and cabozantinib are "smart drugs" that block the blood supply to tumours (by targeting VEGF, a protein that helps cancers grow new blood vessels). They come as pills taken daily.

Side effects: High blood pressure, diarrhea, hand-foot syndrome (painful red palms/soles), fatigue.

3. Surgery (Cytoreductive Nephrectomy) In selected patients with metastatic disease, removing the kidney tumour (even though cancer has spread) can help the immune system and targeted drugs work better. This is not suitable for everyone—your oncologist will advise.

Does Chemotherapy Work for Kidney Cancer?

No—traditional chemotherapy is largely ineffective against kidney cancer. That's why we use immunotherapy and targeted therapy instead, which work much better and have revolutionised outcomes over the past 15 years.

What About Radiotherapy?

Kidney cancer is also resistant to radiotherapy. However, radiation can be used for:

• Pain relief from bone metastases
• Brain metastases (stereotactic radiosurgery)

It's not used to treat the main kidney tumour.

What's My Prognosis?

Prognosis depends entirely on the stage at diagnosis:

• Stage I (small, confined to kidney): > 90% cure rate with surgery
• Stage II-III (larger or locally advanced): 60-85% 5-year survival
• Stage IV (metastatic): Historically poor (~10-15%), but modern immunotherapy has improved median survival to 3-5 years in many patients, and some achieve long-term remission

What Happens After Treatment?

Follow-Up: You'll need regular scans (CT or MRI) to check for recurrence. The frequency depends on your cancer's stage and grade:

• Low-risk: Annual scans for 3-5 years
• High-risk: Scans every 3-6 months for several years, then annually for life

Late Recurrences: Kidney cancer can come back even 10+ years after surgery, so long-term follow-up is important.

Living with One Kidney: If you had a radical nephrectomy, you can live a normal life with one kidney, but you should:

• Stay hydrated
• Avoid nephrotoxic drugs (NSAIDs like ibuprofen; discuss with your doctor)
• Control blood pressure and diabetes
• Have annual kidney function checks

Key Takeaways

1. Most kidney cancers are now found early, before symptoms, which means better cure rates.
2. Surgery (partial or radical nephrectomy) is the only cure for localised kidney cancer.
3. Kidney cancer doesn't respond to traditional chemotherapy, but modern immunotherapy and targeted therapy have transformed outcomes for advanced disease.
4. Even with one kidney, you can live a normal, healthy life.
5. Long-term follow-up is essential, as kidney cancer can recur years later.

---

15. Evidence and Guidelines

This topic is based on high-level evidence from randomised controlled trials, systematic reviews, and international guidelines.

Key Guidelines:

• European Association of Urology (EAU) Guidelines on Renal Cell Carcinoma (2023) [18]
• National Comprehensive Cancer Network (NCCN) Kidney Cancer Guidelines (2024) [26]
• NICE NG12: Suspected Cancer Recognition and Referral (2021)
• American Urological Association (AUA) Guidelines on Renal Mass and Localised Renal Cancer (2021) [19]

Landmark Trials:

• CheckMate 214: Nivolumab + Ipilimumab vs Sunitinib in mRCC [27]
• KEYNOTE-426: Pembrolizumab + Axitinib vs Sunitinib [28]
• CARMENA: Cytoreductive Nephrectomy + Sunitinib vs Sunitinib Alone [36]
• KEYNOTE-564: Adjuvant Pembrolizumab in High-Risk RCC [41]

---

16. References

1. Capitanio U, Bensalah K, Bex A, et al. Epidemiology of Renal Cell Carcinoma. Eur Urol. 2019;75(1):74-84. PMID: 30243799.

2. Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020;11(3):79-87. PMID: 32494314.

3. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98(18):1331-1334. PMID: 16985252.

4. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. PMID: 33538338.

5. Scelo G, Larose TL. Epidemiology and Risk Factors for Kidney Cancer. J Clin Oncol. 2018;36(36):3574-3581. PMID: 30372392.

6. Neuzillet Y, Tillou X, Mathieu R, et al. Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol. 2011;60(2):366-373. PMID: 21458154.

7. Schmidt LS, Linehan WM. Genetic predisposition to kidney cancer. Semin Oncol. 2016;43(5):566-574. PMID: 27899187.

8. Sato Y, Yoshizato T, Shiraishi Y, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013;45(8):860-867. PMID: 23797736.

9. Jonasch E, Donskov F, Iliopoulos O, et al. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021;385(22):2036-2046. PMID: 34818478.

10. Lee CT, Katz J, Fearn PA, Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol. 2002;7(4):135-140. PMID: 12474528.

11. Kershen RT, Shevlin B, Stephenson AJ. Varicocele as presentation of renal cell carcinoma. Rev Urol. 2004;6(1):42-44. PMID: 16985561.

12. Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. Rev Urol. 2002;4(4):163-170. PMID: 16985675.

13. Boxer RJ, Waisman J, Lieber MM, Mampaso FM, Skinner DG. Renal carcinoma: computer analysis of 96 patients treated by nephrectomy. J Urol. 1979;122(5):598-601. PMID: 501785.

14. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794-5799. PMID: 19826129.

15. Silverman SG, Pedrosa I, Ellis JH, et al. Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment. Radiology. 2019;292(2):475-488. PMID: 31210616.

16. Marconi L, Dabestani S, Lam TB, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol. 2016;69(4):660-673. PMID: 26323946.

17. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016;70(1):93-105. PMID: 26935559.

18. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. 2022;82(4):399-410. PMID: 35853991.

19. Campbell SC, Uzzo RG, Karam JA, et al. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline Part I. J Urol. 2021;206(2):199-208. PMID: 33914621.

20. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011;59(4):543-552. PMID: 21186077.

21. Choi JE, You JH, Kim DK, Rha KH, Lee SH. Comparison of perioperative outcomes between robotic and laparoscopic partial nephrectomy: a systematic review and meta-analysis. Eur Urol. 2015;67(5):891-901. PMID: 25572825.

22. Kwon T, Lee JL, You D, et al. Impact of Surgery Type on Survival Outcome in Patients with T1a Renal Cell Carcinoma: A Korean Multicenter Study. J Korean Med Sci. 2016;31(7):1073-1078. PMID: 27366005.

23. Blute ML, Leibovich BC, Lohse CM, Cheville JC, Zincke H. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int. 2004;94(1):33-41. PMID: 15217427.

24. Smaldone MC, Kutikov A, Egleston BL, et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer. 2012;118(4):997-1006. PMID: 21766302.

25. Katsanos K, Mailli L, Krokidis M, McGrath A, Sabharwal T, Adam A. Systematic review and meta-analysis of thermal ablation versus surgical nephrectomy for small renal tumours. Cardiovasc Intervent Radiol. 2014;37(2):427-437. PMID: 24482030.

26. National Comprehensive Cancer Network. Kidney Cancer (Version 4.2024). Available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf

27. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277-1290. PMID: 29562145.

28. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116-1127. PMID: 30779529.

29. Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021;384(9):829-841. PMID: 33657295.

30. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124. PMID: 17215529.

31. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061-1068. PMID: 20100962.

32. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1814-1823. PMID: 26406150.

33. Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473-1482. PMID: 26482279.

34. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1803-1813. PMID: 26406148.

35. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655-1659. PMID: 11759643.

36. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018;379(5):417-427. PMID: 29860937.

37. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011;117(13):2873-2882. PMID: 21692048.

38. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 18 Regs Research Data. National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021.

39. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97(1):1663-1671. PMID: 12655523.

40. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168(6):2395-2400. PMID: 12441925.

41. Choueiri TK, Tomczak P, Park SH, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med. 2021;385(8):683-694. PMID: 34407342.

42. McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749-757. PMID: 29867230.